Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4221809 | 0.85 | ADRA2C (0.60) | ADRA2CADRA1AADRA1DADRA1BTAAR1 | |
| SCHEMBL632163 | 0.75 | ADRA2C (0.58) | ADRA2CADRA1AADRA1DADRA1BTAAR1 | |
| SCHEMBL2744736 | 0.75 | ADRA1D (0.55) | ADRA2CADRA1AADRA1DADRA1BTAAR1 | |
| SCHEMBL8212676 | 0.71 | TAAR1 (0.55) | TAAR1 | |
| SCHEMBL8212500 | 0.71 | MAP3K8 (0.62) | TAAR1 | |
| SCHEMBL633081 | 0.70 | ADRA2C (0.67) | ADRA2CADRA1AADRA1DADRA1BTAAR1 | |
| SCHEMBL29450019 | 0.70 | KDM4E (0.69) | — | |
| SCHEMBL28711239 | 0.70 | KDM4E (0.69) | — | |
| SCHEMBL8211595 | 0.69 | TAAR1 (0.70) | ADRA2CTAAR1 | |
| SCHEMBL2626804 | 0.69 | DAO (0.50) | ADRA2CADRA1AADRA1DADRA1BTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586617-B2 | Aminomethyl-4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2076497-B1 | AMINOMETHYL-4-IMIDAZOLES | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | disclosed |
| EP-2076497-A1 | AMINOMETHYL-4-IMIDAZOLES | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | US | disclosed |
| WO-2008046757-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | INMT, HTR4, MC4R | ADRA2C 275/4885ADRA1A 415/4885ADRA1D 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.